Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?

Lignende værker

• Intestinal SGLT1 as a therapeutic target in COVID‐19‐related diabetes: A “two‐edged sword” hypothesis
  af: Koufakis, Theocharis, et al.
  Udgivet: (2021)
• The Relationship between Primary Hyperparathyroidism and Thrombotic Events: Report of Three Cases and a Review of Potential Mechanisms
  af: Koufakis, Theocharis, et al.
  Udgivet: (2018)
• Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases
  af: Koufakis, Theocharis, et al.
  Udgivet: (2021)
• Results of the First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults further highlight the need for a novel diabetes classification system
  af: Koufakis, Theocharis, et al.
  Udgivet: (2018)
• Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun
  af: Karras, Spyridon N, et al.
  Udgivet: (2019)